

security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: July 30, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-18065 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 28, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-17955 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Chattem Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug  | Schedule |
|---|----------|
| 4-Methoxyamphetamine (7411) ....                    | I        |
| Difenoxin (9168) .....                              | I        |
| Amphetamine (1100) .....                            | II       |
| Methamphetamine (1105) .....                        | II       |
| Methylphenidate (1724) .....                        | II       |
| Pentobarbital (2270) .....                          | II       |
| Codeine (9050) .....                                | II       |
| Oxycodone (9143) .....                              | II       |
| Hydrocodone (9193) .....                            | II       |
| Meperidine (9230) .....                             | II       |
| Dextropropoxyphene, bulk (non-dosage forms) (9273). | II       |
| Morphine (9300) .....                               | II       |
| Thebaine (9333) .....                               | II       |
| Noroxymorphone (9668) .....                         | II       |
| Alfentanil (9737) .....                             | II       |
| Sufentanil (9740) .....                             | II       |
| Fentanyl (9801) .....                               | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-17961 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II.

The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-17962 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

| Drug                          | Schedule |
|-------------------------------|----------|
| Amphetamine (1100) .....      | II       |
| Lisdexamfetamine (1205) ..... | II       |
| Methylphenidate (1724) .....  | II       |
| Methadone (9250) .....        | II       |

| Drug                              | Schedule |
|-----------------------------------|----------|
| Methadone intermediate (9254) ... | II       |

The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-17963 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 11, 2008, American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug  | Schedule |
|---|----------|
| Gamma hydroxybutyric acid (2010).             | I        |
| Ibogaine (7260) .....                         | I        |
| Lysergic acid diethylamide (7315) .....       | I        |
| Tetrahydrocannabinols (7370) .....            | I        |
| Dimethyltryptamine (7435) .....               | I        |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). | I        |
| Dihydromorphine (9145) .....                  | I        |
| Normorphine (9313) .....                      | I        |
| Amphetamine (1100) .....                      | II       |
| Methamphetamine (1105) .....                  | II       |
| Amobarbital (2125) .....                      | II       |
| Phencyclidine (7471) .....                    | II       |
| Phenylacetone (8501) .....                    | II       |
| Cocaine (9041) .....                          | II       |
| Codeine (9050) .....                          | II       |
| Dihydrocodeine (9120) .....                   | II       |
| Oxycodone (9143) .....                        | II       |
| Hydromorphone (9150) .....                    | II       |

| Drug  | Schedule |
|---|----------|
| Ecgonine (9180) .....                               | II       |
| Hydrocodone (9193) .....                            | II       |
| Meperidine (9230) .....                             | II       |
| Metazocine (9240) .....                             | II       |
| Dextropropoxyphene, bulk (non-dosage forms) (9273). | II       |
| Morphine (9300) .....                               | II       |
| Oripavine (9330) .....                              | II       |
| Thebaine (9333) .....                               | II       |
| Oxymorphone (9652) .....                            | II       |
| Phenazocine (9715) .....                            | II       |
| Fentanyl (9801) .....                               | II       |

The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 29, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-17971 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 23, 2008, Austin Pharma, LLC., 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug                                | Schedule |
|-------------------------------------|----------|
| Marihuana (7360) .....              | I        |
| Tetrahydrocannabinols (7370) .....  | I        |
| Alphamethadol (9605) .....          | I        |
| Nabilone (7379) .....               | II       |
| Methadone (9250) .....              | II       |
| Methadone Intermediate (9254) ...   | II       |
| Levo-alphaacetyl-methadol (9648) .. | II       |
| Alfentanil (9737) .....             | II       |

| Drug                      | Schedule |
|---------------------------|----------|
| Remifentanil (9739) ..... | II       |
| Sufentanil (9740) .....   | II       |
| Fentanyl (9801) .....     | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008.

Dated: July 30, 2008.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator/Deputy Chief of Operation, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E8-18046 Filed 8-5-08; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 27, 2008, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug                         | Schedule |
|------------------------------|----------|
| Dihydromorphine (9145) ..... | I        |
| Amphetamine (1100) .....     | II       |
| Methamphetamine (1105) ..... | II       |
| Amobarbital (2125) .....     | II       |
| Pentobarbital (2270) .....   | II       |
| Secobarbital (2315) .....    | II       |
| Phenylacetone (8501) .....   | II       |
| Cocaine (9041) .....         | II       |
| Codeine (9050) .....         | II       |
| Dihydrocodeine (9120) .....  | II       |
| Oxycodone (9143) .....       | II       |